CancerNetwork® spoke with James R. Berenson, MD, president and medical director of the Berenson Cancer Center, and founder of the Institute for Myeloma & Bone Cancer Research, about toxicities associated with ruxolitinib (Jakafi) combination therapy, as well as strategies for reducing them. Additionally, the synergistic effects of adding ruxolitinib to selinexor were discussed.
Best Doctors for Multiple Myeloma in Los Angeles
U.S. News & World Report "Best Doctors for Myeloma in Los Angeles" Article